Immunic(DE:10V)
€7.00+0.11 (+8.93%)
DE:10V
Immunic financials statements
€7.00
At close:+0.11 (+8.93%)
Immunic (10V) Ratios
4 Followers
Immunic Ratios
DE:10V's free cash flow for Q2 2026 was $-31.25M. For the 2026 fiscal year, DE:10V's free cash flow was decreased by $-249.00K and operating cash flow was $-31.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.75 | 1.77 | 2.12 | 9.62 | 9.21 |
| Quick Ratio | 0.75 | 1.77 | 2.12 | 9.20 | 9.21 |
| Cash Ratio | 0.51 | 1.61 | 1.89 | 8.16 | 7.62 |
| Solvency Ratio | -3.16 | -4.47 | -3.69 | -8.55 | -7.75 |
| Operating Cash Flow Ratio | -2.80 | -3.82 | -2.86 | -4.98 | -7.30 |
| Short-Term Operating Cash Flow Coverage | -182.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -7.86M | $ 16.89M | $ 27.17M | $ 111.80M | $ 93.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | -0.10 | 0.05 | 0.05 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | -0.11 | 0.05 | 0.04 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -3.60 | 2.22 | 1.88 | 1.12 | 1.09 |
| Debt Service Coverage Ratio | -206.39 | 0.00 | 0.00 | -83.04 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -114.78 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.10 | 0.03 | 0.08 | 0.04 |
| Net Debt to EBITDA | 0.15 | 0.35 | 0.46 | 1.22 | 0.94 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.13% | 102.50% | 94.35% | 100.77% | 101.40% |
| Return on Assets (ROA) | -404.01% | -245.93% | -172.40% | -94.25% | -66.82% |
| Return on Equity (ROE) | 1456.20% | -545.37% | -323.57% | -105.91% | -73.12% |
| Return on Capital Employed (ROCE) | 1572.16% | -524.54% | -335.55% | -104.20% | -71.78% |
| Return on Invested Capital (ROIC) | 1693.37% | -504.56% | -327.85% | -103.68% | -71.55% |
| Return on Tangible Assets | -404.01% | -245.93% | -172.40% | -94.25% | -87.58% |
| Earnings Yield | -116.88% | -100.33% | -140.81% | -270.29% | -41.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -5.51 | -8.46 | -1.60 | -2.05 | -3.52 |
| Free Cash Flow Per Share | -5.52 | -8.49 | -1.61 | -2.05 | -3.52 |
| Dividend Paid and CapEx Coverage Ratio | -532.96 | -321.08 | -212.06 | -581.64 | -1242.28 |
| Capital Expenditure Coverage Ratio | -532.96 | -321.08 | -212.06 | -581.64 | -1242.28 |
| Operating Cash Flow Coverage Ratio | -125.45 | -84.43 | -53.09 | -41.68 | -83.90 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -103.40% | -84.88% | -107.04% | -146.49% | -36.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.86 | -1.00 | -0.71 | -0.37 | -2.44 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -12.46 | 5.44 | 2.30 | 0.39 | 1.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.97 | -1.18 | -0.93 | -0.68 | -2.72 |
| Price-to-Operating Cash Flow Ratio | -0.97 | -1.18 | -0.94 | -0.68 | -2.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.02 | 0.02 | 0.10 | -0.06 |
| Enterprise Value Multiple | -0.70 | -0.65 | -0.21 | 0.70 | -1.53 |
| Enterprise Value | 68.34M | 65.51M | 21.14M | -60.64M | 140.49M |
| EV to EBITDA | -0.70 | -0.65 | -0.21 | 0.70 | -1.53 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.79 | -0.77 | -0.30 | 0.93 | -1.69 |
| EV to Operating Cash Flow | -0.80 | -0.77 | -0.30 | 0.93 | -1.69 |
| Tangible Book Value Per Share | -0.43 | 1.84 | 0.65 | 3.57 | 3.98 |
| Shareholders’ Equity Per Share | -0.43 | 1.84 | 0.65 | 3.57 | 5.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -6.24 | -10.03 | -2.11 | -3.78 | -3.93 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.94 | 1.39 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.88 | 0.84 | 0.76 | 0.54 | 0.90 |
Currency in USD
